Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Randomized comparison within the endoscopic esophageal varices ligation versus non-selective beta-blocker in the primary prevention of esophageal variceal bleeding in patients with HCC.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taipei Veterans General Hospital, Taiwan
• Treatments: Propranolol

Criteria

Inclusion Criteria:

• Between 20 and 80 years old

• Hepatocellular carcinoma (HCC) associated with esophageal varices

• F2 or F3 esophageal varices (Beppu et al classification)

• Hepatocellular carcinoma (HCC) associated with portal thrombosis

Exclusion Criteria:

• History of esophageal variceal bleeding

• Had received endoscopic variceal ligation (EVL) or endoscopic injection sclerotherapy (EIS)

• Pregnancy, or the patients with other terminal illness (such as other terminal cancers, heart failure, renal failure...)

• Propranolol contraindications (such as atrioventricular block, heart failure, chronic obstructive pulmonary disease, asthma, poorly controlled diabetes, severe peripheral arterial disease...)